Trial reportAddiction (Abingdon, England)2021
Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
Trial report in Addiction (Abingdon, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03248947 (Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: Clinical Trials Network 0075
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes.Pain management · 2024Pooled it
- Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative.PloS one · 2024Trial
- Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.Addiction (Abingdon, England) · 2022Trial
- Pharmacists expand access to contingency management in patients with substance use disorders.The mental health clinician · 2026Article
- Primary Care Training and Education in Addiction Medicine Fellowship: expanding the addiction medicine workforce.BMC medical education · 2025Article
- Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder.Drug and alcohol dependence · 2025Article
- Pharmacy-based preventive services for opioid use disorder: a survey of U.S. pharmacists.Addiction science & clinical practice · 2024Article
- CTN-0138: adaptation, implementation, and cluster randomized trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool-a protocol paper.Addiction science & clinical practice · 2024Article
- Access and care for people with opioid use disorder in U.S. skilled nursing facilities: A policy commentary.The International journal on drug policy · 2024Article
- Delivering MOUD to the Underserved: How Can Pharmacies Really Help?Journal of studies on alcohol and drugs · 2024Article
- Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations.Addiction science & clinical practice · 2024Article
- Article
- Assessing suboxone access in community pharmacies: Secret shopper model.Exploratory research in clinical and social pharmacy · 2023Article
- Perspectives on and experiences of emergency department-initiated buprenorphine among clinical pharmacists: A multi-site qualitative study.Journal of substance use and addiction treatment · 2023Article
- Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.Substance abuse · 2023Article
- Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.Substance abuse treatment, prevention, and policy · 2023Article
- Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care.Southern medical journal · 2023Article
- Community-Centered Patient Journey Map in Opioid Use Disorder: A Tool to Address Compassion Fatigue among Community Pharmacists.Pharmacy (Basel, Switzerland) · 2023Article
- Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies.The New England journal of medicine · 2023Article
- Promising practices and pockets of excellence: Community pharmacists supporting wellness for reproductive-age women.Health services research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsPhysician and pharmacist collaboration may help address the shortage of buprenorphine-waivered physicians and improve care for patients with opioid use disorder (OUD). This study investigated the feasibility and acceptability of a new collaborative care model involving buprenorphine-waivered physicians and community pharmacists.
designNonrandomized, single-arm, open-label feasibility trial.
settingThree office-based buprenorphine treatment (OBBT) clinics and three community pharmacies in the United States.
participantsSix physicians, six pharmacists, and 71 patients aged ≥18 years with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) OUD on buprenorphine maintenance.
interventionAfter screening, eligible patients' buprenorphine care was transferred from their OBBT physician to a community pharmacist for 6 months. MEASUREMENTS: Primary outcomes included recruitment, treatment retention and adherence, and opioid use. Secondary outcomes were intervention fidelity, pharmacists' use of prescription drug monitoring program (PDMP), participant safety, and satisfaction with treatment delivery.
findingsA high proportion (93.4%, 71/76) of eligible participants enrolled into the study. There were high rates of treatment retention (88.7%) and adherence (95.3%) at the end of the study. The proportion of opioid-positive urine drug screens (UDSs) among complete cases (i.e. those with all six UDSs collected during 6 months) at month 6 was (4.9%, 3/61). Intervention fidelity was excellent. Pharmacists used PDMP at 96.8% of visits. There were no opioid-related safety events. Over 90% of patients endorsed that they were "very satisfied with their experience and the quality of treatment offered," that "treatment transfer from physician's office to the pharmacy was not difficult at all," and that "holding buprenorphine visits at the same place the medication is dispensed was very or extremely useful/convenient." Similarly, positive ratings of satisfaction were found among physicians/pharmacists.
conclusionsA collaborative care model for people with opioid use disorder that involves buprenorphine-waivered physicians and community pharmacists appears to be feasible to operate in the United States and have high acceptability to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.